---
document_datetime: 2025-11-23 08:04:53
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/rasilez-hct.html
document_name: rasilez-hct.html
version: success
processing_time: 0.1130816
conversion_datetime: 2025-12-26 11:04:10.588847
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Rasilez HCT

[RSS](/en/individual-human-medicine.xml/65862)

##### Withdrawn

This medicine's authorisation has been withdrawn

aliskiren / hydrochlorothiazide

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Rasilez HCT](#news-on)
- [More information on Rasilez HCT](#more-information-on-rasilez-hct-1119)
- [More information on Rasilez HCT](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 20 December 2021, the European Commission withdrew the marketing authorisation for Rasilez HCT (aliskiren / hydrochlorothiazide) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Noden Pharma DAC, which notified the European Commission of its decision to permanently discontinue the marketing of the product in the EU for commercial reasons.

Rasilez HCT was granted marketing authorisation in the EU on 16 January 2009 for the treatment of essential hypertension. The marketing authorisation was initially valid for a 5-year period. It was subsequently renewed for an additional 5-year period in 2013. It was then granted unlimited validity in 2018. The product had not been marketed in the EU since 16 January 2009.

The European Public Assessment Report (EPAR) for Rasilez HCT is updated to indicate that the marketing authorisation is no longer valid.

Rasilez HCT : EPAR - Medicine overview

English (EN) (696.64 KB - PDF)

**First published:** 09/02/2009

**Last updated:** 20/05/2022

[View](/en/documents/overview/rasilez-hct-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-665)

български (BG) (768.25 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/bg/documents/overview/rasilez-hct-epar-medicine-overview_bg.pdf)

español (ES) (670.49 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/es/documents/overview/rasilez-hct-epar-medicine-overview_es.pdf)

čeština (CS) (750.7 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/cs/documents/overview/rasilez-hct-epar-medicine-overview_cs.pdf)

dansk (DA) (668.78 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/da/documents/overview/rasilez-hct-epar-medicine-overview_da.pdf)

Deutsch (DE) (673.35 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/de/documents/overview/rasilez-hct-epar-medicine-overview_de.pdf)

eesti keel (ET) (667.58 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/et/documents/overview/rasilez-hct-epar-medicine-overview_et.pdf)

ελληνικά (EL) (779.38 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/el/documents/overview/rasilez-hct-epar-medicine-overview_el.pdf)

français (FR) (677.62 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/fr/documents/overview/rasilez-hct-epar-medicine-overview_fr.pdf)

hrvatski (HR) (692.82 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/hr/documents/overview/rasilez-hct-epar-medicine-overview_hr.pdf)

italiano (IT) (669.57 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/it/documents/overview/rasilez-hct-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (753.72 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/lv/documents/overview/rasilez-hct-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (698.69 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/lt/documents/overview/rasilez-hct-epar-medicine-overview_lt.pdf)

magyar (HU) (740.98 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/hu/documents/overview/rasilez-hct-epar-medicine-overview_hu.pdf)

Malti (MT) (759.64 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/mt/documents/overview/rasilez-hct-epar-medicine-overview_mt.pdf)

Nederlands (NL) (669.39 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/nl/documents/overview/rasilez-hct-epar-medicine-overview_nl.pdf)

polski (PL) (746.01 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/pl/documents/overview/rasilez-hct-epar-medicine-overview_pl.pdf)

português (PT) (670.4 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/pt/documents/overview/rasilez-hct-epar-medicine-overview_pt.pdf)

română (RO) (706.3 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/ro/documents/overview/rasilez-hct-epar-medicine-overview_ro.pdf)

slovenčina (SK) (745.79 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/sk/documents/overview/rasilez-hct-epar-medicine-overview_sk.pdf)

slovenščina (SL) (737.22 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/sl/documents/overview/rasilez-hct-epar-medicine-overview_sl.pdf)

Suomi (FI) (667.7 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/fi/documents/overview/rasilez-hct-epar-medicine-overview_fi.pdf)

svenska (SV) (668.64 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/sv/documents/overview/rasilez-hct-epar-medicine-overview_sv.pdf)

## Product information

Rasilez HCT : EPAR - Product Information

English (EN) (1.65 MB - PDF)

**First published:** 05/06/2009

**Last updated:** 20/05/2022

[View](/en/documents/product-information/rasilez-hct-epar-product-information_en.pdf)

[Other languages (20)](#file-language-dropdown-513)

български (BG) (4.37 MB - PDF)

**First published:**

05/06/2009

**Last updated:**

20/05/2022

[View](/bg/documents/product-information/rasilez-hct-epar-product-information_bg.pdf)

español (ES) (1.73 MB - PDF)

**First published:**

05/06/2009

**Last updated:**

20/05/2022

[View](/es/documents/product-information/rasilez-hct-epar-product-information_es.pdf)

čeština (CS) (3.41 MB - PDF)

**First published:**

05/06/2009

**Last updated:**

20/05/2022

[View](/cs/documents/product-information/rasilez-hct-epar-product-information_cs.pdf)

dansk (DA) (1.67 MB - PDF)

**First published:**

05/06/2009

**Last updated:**

20/05/2022

[View](/da/documents/product-information/rasilez-hct-epar-product-information_da.pdf)

Deutsch (DE) (1.76 MB - PDF)

**First published:**

05/06/2009

**Last updated:**

20/05/2022

[View](/de/documents/product-information/rasilez-hct-epar-product-information_de.pdf)

eesti keel (ET) (1.72 MB - PDF)

**First published:**

05/06/2009

**Last updated:**

20/05/2022

[View](/et/documents/product-information/rasilez-hct-epar-product-information_et.pdf)

ελληνικά (EL) (4.48 MB - PDF)

**First published:**

05/06/2009

**Last updated:**

20/05/2022

[View](/el/documents/product-information/rasilez-hct-epar-product-information_el.pdf)

français (FR) (1.58 MB - PDF)

**First published:**

05/06/2009

**Last updated:**

20/05/2022

[View](/fr/documents/product-information/rasilez-hct-epar-product-information_fr.pdf)

hrvatski (HR) (1.8 MB - PDF)

**First published:**

05/06/2009

**Last updated:**

20/05/2022

[View](/hr/documents/product-information/rasilez-hct-epar-product-information_hr.pdf)

íslenska (IS) (1.66 MB - PDF)

**First published:**

05/06/2009

**Last updated:**

20/05/2022

[View](/is/documents/product-information/rasilez-hct-epar-product-information_is.pdf)

italiano (IT) (1.91 MB - PDF)

**First published:**

05/06/2009

**Last updated:**

20/05/2022

[View](/it/documents/product-information/rasilez-hct-epar-product-information_it.pdf)

latviešu valoda (LV) (3.58 MB - PDF)

**First published:**

05/06/2009

**Last updated:**

20/05/2022

[View](/lv/documents/product-information/rasilez-hct-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.02 MB - PDF)

**First published:**

05/06/2009

**Last updated:**

20/05/2022

[View](/lt/documents/product-information/rasilez-hct-epar-product-information_lt.pdf)

magyar (HU) (3.46 MB - PDF)

**First published:**

05/06/2009

**Last updated:**

20/05/2022

[View](/hu/documents/product-information/rasilez-hct-epar-product-information_hu.pdf)

Malti (MT) (3.48 MB - PDF)

**First published:**

05/06/2009

**Last updated:**

20/05/2022

[View](/mt/documents/product-information/rasilez-hct-epar-product-information_mt.pdf)

Nederlands (NL) (1.77 MB - PDF)

**First published:**

05/06/2009

**Last updated:**

20/05/2022

[View](/nl/documents/product-information/rasilez-hct-epar-product-information_nl.pdf)

norsk (NO) (1.73 MB - PDF)

**First published:**

05/06/2009

**Last updated:**

20/05/2022

[View](/no/documents/product-information/rasilez-hct-epar-product-information_no.pdf)

polski (PL) (3.52 MB - PDF)

**First published:**

05/06/2009

**Last updated:**

20/05/2022

[View](/pl/documents/product-information/rasilez-hct-epar-product-information_pl.pdf)

português (PT) (1.67 MB - PDF)

**First published:**

05/06/2009

**Last updated:**

20/05/2022

[View](/pt/documents/product-information/rasilez-hct-epar-product-information_pt.pdf)

Suomi (FI) (1.68 MB - PDF)

**First published:**

05/06/2009

**Last updated:**

20/05/2022

[View](/fi/documents/product-information/rasilez-hct-epar-product-information_fi.pdf)

**Latest procedure affecting product information:** 20/12/2021

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Rasilez HCT : EPAR - All Authorised presentations

English (EN) (887.22 KB - PDF)

**First published:** 09/02/2009

**Last updated:** 20/05/2022

[View](/en/documents/all-authorised-presentations/rasilez-hct-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-692)

български (BG) (1021.35 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/bg/documents/all-authorised-presentations/rasilez-hct-epar-all-authorised-presentations_bg.pdf)

español (ES) (744.52 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/es/documents/all-authorised-presentations/rasilez-hct-epar-all-authorised-presentations_es.pdf)

čeština (CS) (977.93 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/cs/documents/all-authorised-presentations/rasilez-hct-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (740.68 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/da/documents/all-authorised-presentations/rasilez-hct-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (895.25 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/de/documents/all-authorised-presentations/rasilez-hct-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (901.89 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/et/documents/all-authorised-presentations/rasilez-hct-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (1.02 MB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/el/documents/all-authorised-presentations/rasilez-hct-epar-all-authorised-presentations_el.pdf)

français (FR) (949.45 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/fr/documents/all-authorised-presentations/rasilez-hct-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (950.76 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/hr/documents/all-authorised-presentations/rasilez-hct-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (935.58 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/is/documents/all-authorised-presentations/rasilez-hct-epar-all-authorised-presentations_is.pdf)

italiano (IT) (943.34 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/it/documents/all-authorised-presentations/rasilez-hct-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (987.16 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/lv/documents/all-authorised-presentations/rasilez-hct-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (946.05 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/lt/documents/all-authorised-presentations/rasilez-hct-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (988.5 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/hu/documents/all-authorised-presentations/rasilez-hct-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (1.05 MB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/mt/documents/all-authorised-presentations/rasilez-hct-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (893.12 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/nl/documents/all-authorised-presentations/rasilez-hct-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (900.08 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/no/documents/all-authorised-presentations/rasilez-hct-epar-all-authorised-presentations_no.pdf)

polski (PL) (974.73 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/pl/documents/all-authorised-presentations/rasilez-hct-epar-all-authorised-presentations_pl.pdf)

português (PT) (902.63 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/pt/documents/all-authorised-presentations/rasilez-hct-epar-all-authorised-presentations_pt.pdf)

română (RO) (904.92 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/ro/documents/all-authorised-presentations/rasilez-hct-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (1021.14 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/sk/documents/all-authorised-presentations/rasilez-hct-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (979.15 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/sl/documents/all-authorised-presentations/rasilez-hct-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (901.15 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/fi/documents/all-authorised-presentations/rasilez-hct-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (936.86 KB - PDF)

**First published:**

09/02/2009

**Last updated:**

20/05/2022

[View](/sv/documents/all-authorised-presentations/rasilez-hct-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Rasilez HCT Active substance

- aliskiren
- hydrochlorothiazide

International non-proprietary name (INN) or common name

- aliskiren
- hydrochlorothiazide

Therapeutic area (MeSH) Hypertension Anatomical therapeutic chemical (ATC) code C09XA52

### Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

### Therapeutic indication

Treatment of essential hypertension in adults.

Rasilez HCT is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone.

Rasilez HCT is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.

## Authorisation details

EMA product number EMEA/H/C/000964 Marketing authorisation holder

Noden Pharma DAC

D'Olier Chambers

Marketing authorisation issued 16/01/2009 Revision 17

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Rasilez HCT : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (1.4 MB - PDF)

**First published:** 05/06/2009

**Last updated:** 20/05/2022

[View](/en/documents/procedural-steps-after/rasilez-hct-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Rasilez-H-C-964-PSUSA-00000089-201409 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/333074/2015

English (EN) (657.38 KB - PDF)

**First published:** 07/07/2015

**Last updated:** 20/05/2022

[View](/en/documents/scientific-conclusion/rasilez-h-c-964-psusa-00000089-201409-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Rasilez HCT-H-C-964-A31-0053 : EPAR - Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC recomm...

English (EN) (646.34 KB - PDF)

**First published:** 02/10/2014

**Last updated:** 20/05/2022

[View](/en/documents/scientific-conclusion/rasilez-hct-h-c-964-a31-0053-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recomm_en.pdf)

Rasilez HCT-H-C-964-PSUV-0060 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/554712/2014

English (EN) (648.5 KB - PDF)

**First published:** 02/10/2014

**Last updated:** 20/05/2022

[View](/en/documents/scientific-conclusion/rasilez-hct-h-c-964-psuv-0060-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Rasilez HCT-H-C-964-A31-0053 : EPAR - Assessment Report - Article 31

Adopted

Reference Number: EMA/PRAC/294920/2014

English (EN) (1.07 MB - PDF)

**First published:** 02/10/2014

**Last updated:** 20/05/2022

[View](/en/documents/variation-report/rasilez-hct-h-c-964-a31-0053-epar-assessment-report-article-31_en.pdf)

Rasilez HCT-H-C-964-WS-0037 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/479605/2012

English (EN) (3.41 MB - PDF)

**First published:** 20/09/2012

**Last updated:** 20/05/2022

[View](/en/documents/variation-report/rasilez-hct-h-c-964-ws-0037-epar-assessment-report-variation_en.pdf)

Rasilez HCT-H-C-964-A20-0026 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/391210/2012

English (EN) (1 MB - PDF)

**First published:** 20/09/2012

**Last updated:** 20/05/2022

[View](/en/documents/variation-report/rasilez-hct-h-c-964-a20-0026-epar-assessment-report-variation_en.pdf)

Rasilez-HCT-964-WS-0069 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/74385/2012

English (EN) (695.37 KB - PDF)

**First published:** 16/03/2012

**Last updated:** 20/05/2022

[View](/en/documents/variation-report/rasilez-hct-964-ws-0069-epar-assessment-report-variation_en.pdf)

## Initial marketing authorisation documents

Rasilez HCT : EPAR - Public assessment report

English (EN) (1.65 MB - PDF)

**First published:** 16/02/2009

**Last updated:** 20/05/2022

[View](/en/documents/assessment-report/rasilez-hct-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Rasilez HCT

Reference Number: EMEA/CHMP/599453/2008

English (EN) (609.57 KB - PDF)

**First published:** 20/11/2008

**Last updated:** 20/05/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-rasilez-hct_en.pdf)

#### News on Rasilez HCT

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2013](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-13-16-may-2013) 17/05/2013

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 February 2012](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-february-2012) 17/02/2012

#### More information on Rasilez HCT

Questions and answers on the review aliskiren-containing medicines

Reference Number: EMA/113677/2012

English (EN) (60.98 KB - PDF)

**First published:** 17/02/2012

**Last updated:** 17/02/2012

[View](/en/documents/medicine-qa/questions-and-answers-review-aliskiren-containing-medicines_en.pdf)

Questions and answers on ongoing review of aliskiren-containing medicines

Reference Number: EMA/990270/2011

English (EN) (65.3 KB - PDF)

**First published:** 22/12/2011

**Last updated:** 22/12/2011

[View](/en/documents/medicine-qa/questions-and-answers-ongoing-review-aliskiren-containing-medicines_en.pdf)

#### More information on Rasilez HCT

- [Renin-angiotensin-system (RAS)-acting agents - referral](/en/medicines/human/referrals/renin-angiotensin-system-ras-acting-agents)
- [Angioedema among patients with hypertension treated with aliskiren or other anti-hypertensive medications in the US - a cohort Study and a nested case-control analysis using health claims data - post-authorisation study](https://catalogues.ema.europa.eu/study/17554)

**This page was last updated on** 20/05/2022

## Share this page

[Back to top](#main-content)